蛋白质基因组表征揭示了HER2-低乳腺癌的亚型特定治疗潜力
Shouping Xu1,2, Keda Yu3, Lei Liu1
1Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|December 27, 2025
概括
这项研究透露了三种不同的HER2-低乳腺癌分子亚型,使用了多分子分析. 这些亚型建议量身定制的疗法,包括内分泌,抗血管原和抗HER2治疗,以改善患者管理.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 低HER2的乳腺癌表现出分子异质性,使精确的患者管理变得复杂.
- 了解分子格局对于开发有针对性的治疗策略至关重要.
研究的目的:
- 执行 HER2 低乳腺癌的纵向多基因分析.
- 识别不同的分子亚型及其潜在的治疗影响.
- 为了描述基因组特征和乳酸修饰景观.
主要方法:
- 在250个低HER2乳腺癌样本中进行了纵向多基因组分析 (基因组学,转录基因组学,蛋白质组学,乳糖组学,蛋白质组学).
- 蛋白质组亚型分类为PS1,PS2和PS3.
- 在外部数据集和患者衍生有机体 (PDO) 模型中验证.
主要成果:
- 鉴定了三种蛋白质亚型:PS1 (雌激素反应),PS2 (血管新生) 和PS3 (增殖/HER2-高类似).
- 与每个亚型相关的独特特征和潜在的治疗策略 (内分泌,抗血管,抗HER2).
- 提供了详细的基因组表征和乳酸盐修饰景观地图.
结论:
- 已识别的蛋白质亚型为HER2-低乳腺癌的精确治疗策略提供了框架.
- 多原子分析揭示了关键的分子特征,这些特征对于推进治疗至关重要.
- 研究结果支持为这种患者群体开发个性化治疗方法.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.5K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
3.7K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K